About
Methergine

Methergine®:
No significant increase in risk of ACS or AMI1

Within this hospital-based sample of over 2.2 million deliveries, only 5 ACS and 3 AMI cases were observed in 138,412 propensity-score matched patients treated with Methergine1

Methergine was not associated with a significant risk of ACS/AMI; estimates were increased only modestly/not at all
Previous Next
The Knowledge Exchange | Help Fight Maternal Mortality

Help the
Knowledge Exchange in the
fight against maternal morbidity and mortality

References
  1. Bateman BT, Huybrechts KF, Hernandez-Diaz S, Liu J, Ecker JL,Avorn J. Methylergonovine maleate and the risk of myocardial ischemia and infarction.>J Obstet Gynecol. 2013;209:459.e1-459.e13.
  2. Austin PC. An Introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behavioral Research. 2011;46:399-424.